Findings

What do systematic reviews say?

3,241 questions · 3,336 findings · 1,340 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,581 · 47.4%GRADE not reported 352 · 10.6%Very low 512 · 15.3%Low 509 · 15.3%Moderate 316 · 9.5%High 66 · 2%

Metformin vs insulin

Quality of life Short‐Form 36 health survey (SF‐36)

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 91 participants
Very low

Treatment of UI after radical: electric or magnetic energy vs no treatment

Quality of life Score assessed using (ICIQ‐SF) or (ICIQ‐SF UI score) · Patients with postprostatectomy UI

1 finding from 1 review

Conservative management for postprostatectomy urinary incontinence 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Low

Intervention not reported

Disease‐specific quality of life or symptoms [mean score at 12 months] · children with obstructive sleep‐disordered breathing

1 finding from 1 review

Tonsillectomy or adenotonsillectomy versus non‐surgical management for obstructive sleep‐disordered breathing in… 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Low

Thyrotropin‐releasing hormone tartrate vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Riluzole vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Idebenone vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Physiotherapy and occupational therapy vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Hydroxytryptophan vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Buspirone vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Medically assisted hydration vs placebo

QoL · adults aged 18 years and older receiving palliative care

1 finding from 1 review

Medically assisted hydration for adults receiving palliative care 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 93 participants
Very low

Fecal microbiota transplantation vs control

Quality‐of‐life scores with use of FMT for induction of remission in CD · Patients with active Crohn's disease

1 finding from 1 review

Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Mepolizumab intravenous (IV) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 369 participants
High

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1164 participants
High

Reslizumab subcutaneous (SC) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Benralizumab subcutaneous (SC) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1541 participants
High

Supported discharge and multidisciplinary home rehabilitation vs (Optimised) usual care

Quality of Life: SF‐36 (physical component) · Older people undergoing hip fracture aftercare

1 finding from 1 review

Multidisciplinary rehabilitation for older people with hip fractures 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
Very low

Exercise vs control group

Health‐related quality of life (mental) · non‐small cell lung cancer

1 finding from 1 review

Exercise training undertaken by people within 12 months of lung resection for non‐small cell lung cancer 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 208 participants
Low

Clozapine: very low dose (up to 149 mg/day) vs standard dose (301 mg/day to 600 mg/day)

Quality of life: clinically important change in quality of life · patients with schizophrenia

1 finding from 1 review

Clozapine dose for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Clozapine: low dose (150 mg/day to 300 mg/day) vs standard dose (301 mg/day to 600 mg/day)

Quality of life: clinically important change in quality of life · patients with schizophrenia

1 finding from 1 review

Clozapine dose for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported